Jafari Shima, Shoghi Melika, Khazdair Mohammad Reza
Cardiovascular Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran.
Department of Clinical Pharmacy, School of Pharmacy, Birjand University of Medical Sciences, Birjand, Iran.
Evid Based Complement Alternat Med. 2023 May 26;2023:8250219. doi: 10.1155/2023/8250219. eCollection 2023.
Cardiovascular diseases (CVDs) are a group of disorders that involve the heart or blood vessels and are the leading cause of mortality worldwide. Natural products have several pharmacological activities, such as anti-inflammatory, antioxidant, and immunoregulatory properties. This review summarizes the possible therapeutic effects of Genistein on CVD. The information from the current review study was obtained by searching for the keywords such as "Genistein", "Cardiac dysfunction", "hypertrophy", and "Ischemia" "lipid profile" in different online database such as PubMed, Scopus, and Google Scholar, until February 2022. The results of the studies showed that genistein intake has a promising effect on improving cardiac dysfunction, ischemia, and reperfusion of the heart, decreasing cardiac toxicity, modulating lipid profile, and lowering blood pressure. The preventive effects of genistein on experimental models of studies were shown through mechanisms such as anti-inflammatory, antioxidant, and immunomodulatory effects. Pharmacological effects of genistein on cardiac dysfunction, cardiac toxicity, lipid profile, and hypertension indicate the possible remedy effect of this agent in the treatment of CVD.
心血管疾病(CVDs)是一组涉及心脏或血管的病症,是全球范围内主要的死亡原因。天然产物具有多种药理活性,如抗炎、抗氧化和免疫调节特性。本综述总结了金雀异黄素对心血管疾病可能的治疗作用。本综述研究的信息是通过在不同的在线数据库(如PubMed、Scopus和谷歌学术)中搜索“金雀异黄素”、“心脏功能障碍”、“肥大”、“缺血”、“血脂谱”等关键词获得的,截至2022年2月。研究结果表明,摄入金雀异黄素对改善心脏功能障碍、心脏缺血和再灌注、降低心脏毒性、调节血脂谱和降低血压具有显著作用。金雀异黄素对实验模型的预防作用是通过抗炎、抗氧化和免疫调节等机制实现的。金雀异黄素对心脏功能障碍、心脏毒性、血脂谱和高血压的药理作用表明该药物在治疗心血管疾病方面可能具有治疗效果。
Evid Based Complement Alternat Med. 2023-5-26
Eur J Pharmacol. 2022-10-15
Curr Pharm Des. 2019
J Ethnopharmacol. 2022-1-10
Chem Biol Interact. 2017-4-25
BMC Complement Med Ther. 2024-2-3
Nat Prod Bioprospect. 2023-9-13
Molecules. 2020-9-21
Front Pharmacol. 2020-4-7